Autonomix Presents Early Preclinical Research on Renal Denervation Sensing Technology

• Autonomix Medical presented early preclinical research on its investigational sensing catheter at TCT 2026, supporting its renal denervation development strategy.
• Healthy swine studies captured electrical activity before and after ablation; findings remain preliminary and require further validation.
• Reduced recorded activity alone does not establish complete or durable denervation.
• The standalone sensing system is the initial U.S. commercialization priority; proposed initial clearance would exclude renal denervation guidance or treatment-verification claims.
• A commercial offering is targeted by the end of 2028, subject to successful development, validation, financing and regulatory authorization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120830PRIMZONEFULLFEED9876008) on November 12, 2026, and is solely responsible for the information contained therein.